Pancragen – 20mg (3ml Pen)

Pancragen is a tetrapeptide associated in this literature with pancreatic tissue and carbohydrate metabolism endpoints. It belongs to the family of short peptide bioregulators developed within a single Russian research programme, which proposes that very short peptide sequences act as tissue-specific regulators of gene expression. The literature is internally coherent and spans several decades, but it originates overwhelmingly from that one institutional tradition and has attracted comparatively little independent international replication.

Pancragen is described in this literature as a short peptide (Lys-Glu-Asp-Trp) developed from work on pancreatic tissue. The mechanistic model proposed by the originating research programme is direct interaction between short peptides and DNA regulatory regions, with sequence-specific binding said to modulate transcription in a tissue-selective manner. Research within this programme reports effects on pancreatic cell differentiation markers and glucose-related parameters in animal models. This proposed mechanism of direct peptide–DNA regulation is not widely adopted in mainstream molecular biology, and the binding model itself remains an open question outside the originating tradition.

The evidence base consists principally of cell culture and animal work published within the originating research programme, alongside observational clinical material. Independent replication outside the originating research programme remains limited, which is the principal caveat applying across this peptide family.

Originating programme

Cell culture and animal research published within the Khavinson institutional tradition.

Proposed mechanism

Direct peptide–DNA interaction model governing tissue-selective transcription.

Tissue focus

Pancreatic cell differentiation markers and glucose-related parameters in animal models.

Peptide chemistry

Very short sequence with correspondingly rapid enzymatic degradation profile.

Replication context

Independent international verification of central findings is limited.